Measurement of Exhaled Nitric Oxide in 456 Lung Cancer Patients Using a Ringdown FENO Analyzer

The objective of this study was to investigate the clinical value of exhaled nitric oxide (NO) for diagnosing lung cancer patients by using a relatively large sample. An online and near-real-time ringdown exhaled NO analyzer calibrated by an electrochemical sensor at clinical was used for breath analysis. A total of 740 breath samples from 284 healthy control subjects (H) and 456 lung cancer patients (LC) were collected. The recorded data included exhaled NO, medications taken within the last half month, demographics, fasting status and smoking status. The LC had a significantly higher level of exhaled NO than the H (H: 21.0 ± 12.1 ppb vs. LC: 34.1 ± 17.2 ppb). The area under the receiver operating characteristic curve for exhaled NO predicting LC and H was 0.728 (sensitivity was 0.798; specificity was 0.55). There was no significant difference in exhaled NO level between groups divided by different types of LC, tumor node metastasis (TNM) stage, sex, smoking status, age, body mass index (BMI) or fasting status. Exhaled NO level alone is not a useful clinical tool for identifying lung cancer, but it should be considered when developing a diagnosis model of lung cancer by using breath analysis.

Download Full-text

Nitric Oxide in Occurrence, Progress and Therapy of Lung Cancer: A Systemic Review and Meta-analysis

10.21203/rs.3.rs-249109/v1 ◽

2021 ◽

Author(s):

Hongbin Zhou ◽

Zhewen Chen ◽

Ying Chen ◽

Jiuke Li ◽

Sa Ye

Keyword(s):

Nitric Oxide ◽

Lung Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Lung Cancer Patients ◽

Time Points ◽

Control Subjects ◽

Significant Difference ◽

Different Populations ◽

Nsclc Patients

Abstract Background: Nitric oxide (NO) plays an important role in lung cancer. However, the results of previous studies about NO in the occurrence, progress and therapy were not consistent. Therefore, we conducted a meta-analysis to evaluate the relationship between NO and lung cancer.Method: We carried out comprehensive search in the databases, and collected related studies. The data of fraction of exhaled nitric oxide (FeNO) or blood NO in different populations (lung cancer patients and control subjects) and different time points (before therapy and after therapy) were extracted by two investigators. A random effect model was applied to analyze the differences of FeNO and blood NO in different populations and different time points. To further compare NO level of each subgroup with different pathological types and different stages, a network meta-analysis (NMA) was performed.Results: 50 studies including 2551 cases and 1691 controls were adopted in this meta-analysis. The FeNO (SMD 3.01, 95% CI 1.89-4.13, p < 0.00001) and blood NO (SMD 1.34, 95% CI 0.84-1.85, p < 0.00001) level in lung cancer patients was much higher than that in control subjects. NMA model indicated blood NO level in each cancer type except SCLC was higher than that in control patients. There was no significant difference of blood NO level among four kinds of lung cancer patients. Blood NO level in LCC patients (SUCRA=83.5%) was the highest. Blood NO level in advanced stage but not early stage was higher than that in control subjects. Patients in advanced stage (SUCRA=95.5%) had the highest blood NO level. No significant difference of FeNO (SMD -0.04, 95% CI -0.46-0.38, p > 0.05) and blood NO level (SMD -0.36, 95% CI -1.08-0.36, p > 0.05) was observed between pretreatment and posttreatment in all patients. However, FeNO level elevated (SMD 0.28, 95% CI 0.04-0.51, p = 0.02) and blood NO level decreased in NSCLC patients (SMD -0.95, 95% CI -1.89-0.00, p = 0.05) after therapy. Conclusion: FeNO and blood NO level would contribute to diagnosis of lung cancer and evaluation of therapy effect, especially for NSCLC patients.

Download Full-text

Exhaled nitric oxide predicts radiation pneumonitis in esophageal and lung cancer patients receiving thoracic radiation

Radiotherapy and Oncology ◽

10.1016/j.radonc.2011.08.035 ◽

2011 ◽

Vol 101 (3) ◽

pp. 443-448 ◽

Cited By ~ 17

Author(s):

Matthew R. McCurdy ◽

Mohamad W. Wazni ◽

Josue Martinez ◽

Mary Frances McAleer ◽

Thomas Guerrero

Keyword(s):

Nitric Oxide ◽

Lung Cancer ◽

Cancer Patients ◽

Radiation Pneumonitis ◽

Exhaled Nitric Oxide ◽

Lung Cancer Patients ◽

Thoracic Radiation

Download Full-text

Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis

BMC Cancer ◽

10.1186/s12885-021-08430-2 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Hongbin Zhou ◽

Jiuke Li ◽

Zhewen Chen ◽

Ying Chen ◽

Sa Ye

Keyword(s):

Nitric Oxide ◽

Lung Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Lung Cancer Patients ◽

Time Points ◽

Control Subjects ◽

Significant Difference ◽

Different Populations ◽

Nsclc Patients

Abstract Background Nitric oxide (NO) plays an important role in lung cancer. However, the results of previous studies about NO in the occurrence, progress and therapy were not consistent. Therefore, we conducted a meta-analysis to evaluate the relationship between NO and lung cancer. Method We carried out comprehensive search in the databases, and collected related studies. The data of fraction of exhaled nitric oxide (FeNO) or blood NO in different populations (lung cancer patients and control subjects) and different time points (before therapy and after therapy) were extracted by two investigators. A random effect model was applied to analyze the differences of FeNO and blood NO in different populations and different time points. To further compare NO level of each subgroup with different pathological types and different stages, a network meta-analysis (NMA) was performed. Results Fifty studies including 2551 cases and 1691 controls were adopted in this meta-analysis. The FeNO (SMD 3.01, 95% CI 1.89–4.13, p < 0.00001) and blood NO (SMD 1.34, 95% CI 0.84–1.85, p < 0.00001) level in lung cancer patients was much higher than that in control subjects. NMA model indicated blood NO level in each cancer type except SCLC was higher than that in control patients. There was no significant difference of blood NO level among four kinds of lung cancer patients. Blood NO level in LCC patients (SUCRA = 83.5%) was the highest. Blood NO level in advanced stage but not early stage was higher than that in control subjects. Patients in advanced stage (SUCRA = 95.5%) had the highest blood NO level. No significant difference of FeNO (SMD -0.04, 95% CI -0.46-0.38, p > 0.05) and blood NO level (SMD -0.36, 95% CI -1.08-0.36, p > 0.05) was observed between pretreatment and posttreatment in all patients. However, FeNO level elevated (SMD 0.28, 95% CI 0.04–0.51, p = 0.02) and blood NO level decreased in NSCLC patients (SMD -0.95, 95% CI -1.89-0.00, p = 0.05) after therapy. Conclusion FeNO and blood NO level would contribute to diagnosis of lung cancer and evaluation of therapy effect, especially for NSCLC patients.

Download Full-text

Venous thromboembolism in non-small cell lung cancer patients who underwent surgery after induction therapy

General Thoracic and Cardiovascular Surgery ◽

10.1007/s11748-020-01351-0 ◽

2020 ◽

Vol 68 (10) ◽

pp. 1156-1162

Author(s):

Yasunori Kaminuma ◽

Masayuki Tanahashi ◽

Eriko Suzuki ◽

Naoko Yoshii ◽

Hiroshi Niwa

Keyword(s):

Lung Cancer ◽

Venous Thromboembolism ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Induction Therapy ◽

Small Cell ◽

Small Cell Lung ◽

Free Survival ◽

Lung Cancer Patients ◽

Significant Difference

Abstract Objectives Lung cancer patients have been reported to have a high incidence of venous thromboembolism (VTE) and a high recurrence rate of VTE. However, there are no detailed reports of VTE in lung cancer patients who underwent surgery after induction therapy. We examined the incidence and clinical features of VTE in these patients. Methods We retrospectively evaluated 89 patients with non-small cell lung cancer who underwent surgery after induction therapy at our department between April 2009 and March 2018. The incidence of VTE, clinical features, and long-term prognosis were retrospectively examined. Results Among the 89 patients, 4 (4.5%) developed VTE, and there was no significant difference in the background characteristics between patients with and without VTE. All four patients developed VTE during preoperative treatment. In the patients with VTE, anticoagulant therapy with oral anticoagulants was administered after heparinization, and the median duration of anticoagulant therapy was 18.7 months. There were no cases of symptomatic VTE recurrence after surgery, regardless of lung cancer recurrence. Although the overall survival (OS) showed no significant difference between patients with and without VTE, the disease-free survival was significantly shorter in patients with VTE than in those without it (median 6.3 vs. 71.6 months, p < 0.01). Conclusions In induction cases, the incidence of VTE was 4.5%, and it can at least be stated that no symptomatic VTE developed or recurred after surgery. Patients with VTE in induction therapy had short progression-free survival and required careful follow-up after surgery.

Download Full-text

Characteristics of asbestos fibers in lung tissue from occupational and environmental asbestos exposure of lung cancer patients in Busan, Korea

Scientific Reports ◽

10.1038/s41598-020-77291-9 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Hyun-Sung Jung ◽

Eun-Kee Park ◽

Jun-Seok Cha ◽

Jae-Won Lee ◽

Jong-Chun Lee ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Lung Tissue ◽

Asbestos Exposure ◽

Coefficient Of Determination ◽

Factors Affecting ◽

Lung Cancer Patients ◽

Asbestos Fibers ◽

Significant Difference ◽

Occupationally Exposed

AbstractThe Asbestos Injury Relief Act in Korea requires that asbestos exposure be assessed through clinical examination and chest computed tomography (CT). However, a more specific measurement of asbestos characteristics in the lung tissue may be appropriate. We aimed to investigate the asbestos burden and characterize asbestos fibers in patients with lung cancer and ultimately assess the relationship between occupational and environmental asbestos exposure and lung cancer in Korea. We evaluated 37 lung cancer patients (LCPs) from Busan. The factors affecting asbestos burden in LCPs were analyzed using a multiple regression analysis. History of asbestos exposure (environmental/occupational), male sex, and old age were the main factors affecting asbestos burden in lung tissues of LCPs. These factors had an approximate 37% adjusted coefficient of determination. There was a significant difference in the length of asbestos fibers (4.06–37.6 µm vs. 4.26–91.7 µm) and aspect ratio (4.5–151.9 vs. 5.6–735.6) between those who were occupationally exposed to asbestos and those who were environmentally exposed (P < 0.01). Therefore, both environmental/occupational exposure to asbestos should be strongly managed to reduce the risk of lung cancer, and exposure should be assessed according to the characteristics of asbestos fibers in the lung tissue.

Download Full-text

Braf and erbB2 mutations correlate with smoking status in lung cancer patients

Experimental and Therapeutic Medicine ◽

10.3892/etm.2012.500 ◽

2012 ◽

Vol 3 (5) ◽

pp. 771-775 ◽

Cited By ~ 12

Author(s):

HIDEFUMI SASAKI ◽

MASAYUKI SHITARA ◽

KEISUKE YOKOTA ◽

KATSUHIRO OKUDA ◽

YU HIKOSAKA ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Smoking Status ◽

Lung Cancer Patients

Download Full-text

Evaluation of chemotherapy response between Paclitaxel-Cisplatin, Paclitaxel -Gemcitabine and Gemcitabine - Cisplatin among non - resectable lung cancer patients, A retrospective study in tertiary care hospital.

Journal of Bangladesh College of Physicians and Surgeons ◽

10.3329/jbcps.v38i4.48977 ◽

2020 ◽

Vol 38 (4) ◽

pp. 172-175

Author(s):

Md Harun Or Rashid ◽

Quadrat E Elahi ◽

Md Ashraful Alam ◽

Fatima Sarker

Keyword(s):

Lung Cancer ◽

Survival Rate ◽

Survival Time ◽

Cancer Patients ◽

Median Survival ◽

Median Survival Time ◽

Chemotherapy Response ◽

Care Hospital ◽

Lung Cancer Patients ◽

Significant Difference

Background: To compare the survival rate of paclitaxel plus cisplatin (PC arm), paclitaxel plus gemcitabine (PG arm) and gemcitabine plus cisplatin (GC arm) in chemotherapy patients with non resectable lung cancer. Methods: This was a retrospective observational study to evaluate chemotherapy response among non resectable lung cancer patients with their survival at cancer center CMH, Dhaka since 01 July 2013 to 31 March 2015. One hundred fifty-four (154) non resectable lung cancer patients were randomly divided into three groups, 50 patients in PC arm, 51 patients in PG arm and 53 patients in GC arm. In PC arm paclitaxel 175 mg/m2 (day 1) with cisplatin 75mg/m2 (day 1), in PG arm Paclitaxel 175 mg/m2 (day 1) with gemcitabine 1000 mg/m2 (days 1 and 8) and in GC arm gemcitabine 1000 mg/m2 (days 1 and 8) with cisplatin 100mg/m2 (day 1). Results: Patients characteristics were similar between the three groups. The overall response rate was 40% in the PC arm,43.1% in the PG arm, 43.4% in the GC arm. The median survival time in PC arm was 8.5 months, in PG arm was 8.8 months, in GC arm was 9.2 months. The major side effect was myelosuppression which accounts 71% patients. The average treatment costs were 57% and 30% lower in PC arm as compared with GC and PG arm respectively. Conclusion: The median survival time, disease free survival time and 1-year survival rate in PC, PG, GC arms without significant difference. Treatment were well tolerable; quality of life parameter was mostly similar but paclitaxel with cisplatin was most cost effective than others chemotherapy regimen. J Bangladesh Coll Phys Surg 2020; 38(4): 172-175

Download Full-text